This site is intended for
healthcare professionals only.


1.800.986.8999
 

 

Enrollment

REBETOL®
(ribavirin)
CRIXIVAN®
(indinavir sulfate)
ISENTRESS®
(raltegravir)
GARDASIL®
[Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]
JANUVIA®
(sitagliptin phosphate)
JANUMET®
(sitagliptin/metformin HCl)
MAXALT®
(rizatriptan benzoate)
SINGULAIR®
(montelukast sodium)
VARICELLA ZOSTER VIRUS-CONTAINING VACCINES


 

Merck Pregnancy Registries

Pregnancy Registries are prospective active data collections in systems which can facilitate the early detection of teratogenicity and other serious adverse experiences in patients who inadvertently or purposefully use a drug during pregnancy. Useful information about the outcome of exposure in pregnancy can best be obtained by the careful collection and analysis of postmarketing surveillance data. Reports of the aggregate data in each Registry are updated annually and are available to health care providers in the U.S. upon request. (In countries outside of the U.S., information is available through the local Merck subsidiary).

To request a report call 1-800-986-8999 or complete the Annual Report Request Form (found on the product page by clicking on the icon to the left) and fax it to the Registry at 267-305-6541. Please include your fax number and a report will be sent to you within 3 business days. We encourage health care providers to report cases of exposure during pregnancy as early in the pregnancy as possible to facilitate the collection of prospective, unbiased information.


CRIXIVAN  |  GARDASIL  |  ISENTRESS  |  JANUVIA  |  JANUMET  |  MAXALT  |  PROQUAD  |  REBETOL  |  SINGULAIR  |  VARIVAX  |  ZOSTAVAX  | 
Enrollment  |  Home  |  Privacy Policy

Copyright 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.